Galvus Tablets 50Mg (1 Box = 2 Strips) (1 Strip = 14 Tablets)

Galvus Tablets Usage And SafetyDosageVildagliptinSide EffectsMonotherapy Common: Dizziness. Uncommon: Hypoglycemia, headache, edema peripheral, constipation & arthralgia. Very Rare: Upper respiratory tract infection & nasopharyngitis. Combination with Metformin Common: Hypoglycemia, tremor, headache, dizziness & nausea. Uncommon: Fatigue. Combination with Sulfonylurea Common: Hypoglycemia, tremor, headache, dizziness & asthenia. Uncommon: Constipation. Very Rare: Nasopharyngitis. Combination with Thiazolidinedione Common: Weight increase & edema peripheral. Uncommon: Hypoglycemia, headache & asthenia. Combination with Metformin and Sulfonylurea Common: Hypoglycemia, dizziness, tremor, hyperhidrosis & asthenia. Combination with Insulin Common: Decreased blood glucose, headache, chills, nausea, gastroesophageal reflux disease. Uncommon: Diarrhea & flatulence.Drug InteractionsVildagliptin has a low potential for interactions with co-administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP450 enzymes, it isnot likely to interact with active substances that are substrates, inhibitors or inducers of these enzymes. As with other oral antidiabetic medicinal products the hypoglycemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.IndicationVildagliptin is indicated for the treatment of type 2 diabetes mellitus in adults:As monotherapy – In patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.As dual oral therapy in combination with – Metformin, in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with metformin.- Sulfonylurea, in patients with insufficient glycemic control despite maximal tolerated dose of a sulfonylurea and for whom metformin is inappropriate due to contraindications or intolerance.- Thiazolidinedione, in patients with insufficient glycemic control and for whom the use of a thiazolidinedione is appropriate. As triple oral therapy in combination with- Sulfonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycemic control.Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycemic control.When not to UseVildagliptin is contraindicated in patients with known hypersensitivity to vildagliptin or to any excipient of the product.